Proactive Investors - Run By Investors For Investors

ImmuPharma banks extra £600,000 from Lanstead agreement

The better-than-expected outcome reflects a trebling in the share price of Immupharma
picture of accounts
The agreement has worked for both parties

Lupus drug developer Immupharma PLC (LON:IMM) has raised £600,000 more than expected from its equity sharing agreement with financier Lanstead Capital, banking £5mln instead of the £4.4mln originally estimated.

The better than expected outcome reflects a trebling in the share price of Immupharma to 82p following increasingly upbeat statements about the progress of the Phase III trial of Lupuzor, its flagship Lupus treatment. Top-line Phase III results are due in the first quarter of 2018.

WATCH: Immupharma 'looking forward and planning for success' with Lupuzor

Immupahrma and Lanstead set up the facility in Feburary 2016, when the drug developer also raised £3.9mln through a placing at 26p.

Tim McCarthy, ImmuPharma’s chairman said in a statement: "Lanstead has been an important supporter of ImmuPharma and we are delighted how effectively the Sharing Agreement has worked for both parties.

READ: Immupharma starts preparations for Lupuzor submission as trial makes good progress

Nicholas Malins-Smith of Lanstead added: “Through the Sharing Agreement with Lanstead, ImmuPharma has been able to benefit, through the increase in its share price, by securing additional funds over and above the original subscription amount.”


View full IMM profile View Profile

ImmuPharma PLC Timeline

Related Articles

Dog skeleton with cannabis plant leaf
July 17 2018
The company's lead drug candidate is a cannabis-derived canine pain medication.
November 23 2018
The Australian regenerative medicine company is developing a portfolio of innovative cellular therapies targeting significant unmet medical needs with a licence-driven strategy.
immunotherapy graphic
September 13 2018
A clinical trial application for the potential cancer treatment is on track to be filed in the current quarter, and that will be followed by patient recruitment towards the end of the year

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use